| gap-pubmed-20260411- | Which specific proteins does UBIAD1 prenylate to regulate cholesterol homeostasi | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does UBIAD1 prenyltransferase activity mechanistically regulate cholesterol | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines neuronal subtype vulnerability in the p53-Puma pathway downstrea | resolved | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why does poly(PR) activate p53 while other dipeptide repeats may use different p | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What upstream mechanisms trigger p53 activation specifically in response to poly | partially_addressed | 0.89 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What triggers the initial microglial activation and CCL-3/-4/-5 upregulation in | open | 0.81 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How does CCL5-CCR5 autophagy inhibition specifically impair CCR5 degradation to | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms link CCR5 activation to mTORC1 hyperactivation in neur | open | 0.84 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | When during AD progression do different neuronal death mechanisms become active? | open | 0.72 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do different modes of neuronal death differentially impact neuroinflammation | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How do novel cell death mechanisms (necroptosis, parthanatos, ferroptosis, cupro | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do artificial ripples compare to endogenous sharp-wave-ripples in supporting | open | 0.75 | 0.00 | 2026-04-11 | 0 | | memory-consolidation |
| gap-pubmed-20260411- | What specific mechanisms link artificial sharp-wave-ripples to countering Alzhei | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Can noninvasive visual stimulation actually induce artificial sharp-wave-ripples | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurophysiology |
| gap-pubmed-20260411- | How do plasma p-tau biomarkers perform in diverse cohorts representative of memo | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What are the optimal plasma p-tau thresholds for AD diagnosis across diverse pop | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How can plasma p-tau assays be standardized across laboratories and platforms fo | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do altered visual cortex-subiculum connections mechanistically contribute to | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What mechanisms drive sex-specific connectivity changes in hippocampal-subicular | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Does the neurodegeneration trajectory differ between male and female RBD patient | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do women with RBD exhibit less violent and fewer sleep behaviors compared to | open | 0.72 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What hormonal mechanisms contribute to sex differences in RBD clinical manifesta | open | 0.77 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms link TFQA treatment to simultaneous increases in multi | open | 0.75 | 0.00 | 2026-04-11 | 0 | | neurotransmitter-biology |
| gap-pubmed-20260411- | How does TFQA binding to TrkB receptor lead to BDNF upregulation given that TrkB | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurotrophin-signaling |
| gap-pubmed-20260411- | What are the regulatory mechanisms controlling PRKN-independent mitophagy recept | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do PRKN-independent mitophagy pathways interact and coordinate with each oth | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Does the SIRT1/caveolin-1/eNOS pathway function similarly in brain endothelial c | open | 0.78 | 0.00 | 2026-04-11 | 0 | | cerebrovascular-neurodegeneration |
| gap-pubmed-20260411- | How does SIRT1 specifically regulate caveolin-1 acetylation to control eNOS acti | resolved | 0.80 | 0.00 | 2026-04-11 | 0 | | vascular-neurodegeneration |
| gap-pubmed-20260411- | Why do control cells with cyclophosphamide pretreatment provide therapeutic bene | open | 0.75 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What mechanism underlies CAR-T cell therapeutic benefit independent of B-cell de | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | Why do anti-CD19 CAR-T cells show opposite effects on EAE across different exper | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How does rutin's promotion of microglial function relate to its anti-inflammator | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What is the molecular mechanism by which rutin inhibits tau aggregation and olig | partially_addressed | 0.87 | 0.00 | 2026-04-11 | 1 | 2026-04-25 | neurodegeneration |
| gap-pubmed-20260411- | How do different ADAM10 isoforms contribute differentially to non-amyloidogenic | open | 0.77 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do current antibodies produce discrepant results when detecting ADAM10 isofo | open | 0.75 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What mechanisms control ADAM10's substrate specificity among its 100+ cleavage t | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does gut microbiota dysbiosis influence the dual protective and harmful role | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What are the specific mechanisms by which gut microbiota regulates microglia-dep | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What are the downstream signaling pathways affected by CD33 isoform switching in | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | Why does genetic deletion of CD33 show no association with AD risk while reduced | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does the CD33 isoform lacking exon 2 mechanistically reduce Alzheimer's dise | resolved | 0.85 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What are the specific molecular mechanisms linking ion channel activation to neu | resolved | 0.83 | 0.00 | 2026-04-11 | 0 | | cellular-neuroscience |
| gap-pubmed-20260411- | How does light penetration depth relate to therapeutic efficacy across different | open | 0.80 | 0.00 | 2026-04-11 | 0 | | photobiomodulation |
| gap-pubmed-20260411- | Why do racial differences in APOE4-biomarker associations exist in neurodegenera | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms explain why APOE4 specifically amplifies the neurotoxi | resolved | 0.85 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Do these Drosophila findings on oxidative stress causality translate to human ta | open | 0.75 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does oxidative stress enhance tau-induced cell cycle activation in post-mito | resolved | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Do other 'synaptic' ASD risk genes also have non-synaptic functions during early | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodevelopment |
| gap-pubmed-20260411- | What is the mechanistic link between SYNGAP1-mediated cytoskeletal dysregulation | open | 0.84 | 0.00 | 2026-04-11 | 0 | | cell-biology |
| gap-pubmed-20260411- | How does SYNGAP1, a 'synaptic' protein, function in pre-synaptic radial glia cel | partially_addressed | 0.89 | 0.00 | 2026-04-11 | 0 | | neurodevelopment |